CL2018000933A1 - Una composición farmacéutica que comprende un anticuerpo anti-factor estimulante de colonias de granulocitos-macrógagos (anti-gm-csf) y vehículos, excipientes o estabilizadores farmacéuticamente aceptables, útil para tratar artritis reumatoide (divisional de la solicitud 696-2015). - Google Patents

Una composición farmacéutica que comprende un anticuerpo anti-factor estimulante de colonias de granulocitos-macrógagos (anti-gm-csf) y vehículos, excipientes o estabilizadores farmacéuticamente aceptables, útil para tratar artritis reumatoide (divisional de la solicitud 696-2015).

Info

Publication number
CL2018000933A1
CL2018000933A1 CL2018000933A CL2018000933A CL2018000933A1 CL 2018000933 A1 CL2018000933 A1 CL 2018000933A1 CL 2018000933 A CL2018000933 A CL 2018000933A CL 2018000933 A CL2018000933 A CL 2018000933A CL 2018000933 A1 CL2018000933 A1 CL 2018000933A1
Authority
CL
Chile
Prior art keywords
strong
excipients
stabilizers
pharmaceutically acceptable
csf
Prior art date
Application number
CL2018000933A
Other languages
English (en)
Inventor
Stefan Haertle
Stephane Leclair
Amgad Shebl
Stefan Steidl
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of CL2018000933A1 publication Critical patent/CL2018000933A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>Una Composición farmacéutica que comprende un anticuerpo anti-factor estimulante de colonias de granulocitos-macrófagos (anti-GM-CSF) y vehículos, excipientes o estabilizadores farmacéuticamente aceptables, donde los vehículos, excipientes o estabilizadores farmacéuticamente aceptables son un regulador que es histidina; un azúcar que es sorbitol; y un tensoactivo no iónico que es TWEEN-80, donde dicho anticuerpo anti-GM-CSF comprende un péptido de cadena pesada variable (donde las CDRs están en negrillas y subrayadas): QVQLVESGGGLVQPGGSLRLSCAAS<u><strong>GFTFSSYWMN</strong></u>WVRQAPGKGLEWVS<strong><u>GIENKYAGGATYYA ASVKG</u></strong>RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR<u><strong>GFGTDF</strong></u>WGQGTLVTVSS; y un péptido de cadena liviana variable ( donde las CDRs estan en negrillas y subrayadas): DlELTQPPSVSVAPGQTARISC<strong><u>SGDSIGKKYAY</u></strong>WYQQKPGQAPVLVIY<strong><u>KKRPS</u></strong>GIPERFSGSNSGN TATLTISGTQAEDEADYYC<strong><u>SAWGDKGM</u></strong>VFGGGTKLTVLGQ. </p>
CL2018000933A 2012-09-20 2018-04-12 Una composición farmacéutica que comprende un anticuerpo anti-factor estimulante de colonias de granulocitos-macrógagos (anti-gm-csf) y vehículos, excipientes o estabilizadores farmacéuticamente aceptables, útil para tratar artritis reumatoide (divisional de la solicitud 696-2015). CL2018000933A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
US201261703871P 2012-09-21 2012-09-21

Publications (1)

Publication Number Publication Date
CL2018000933A1 true CL2018000933A1 (es) 2018-07-20

Family

ID=46963526

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015000696A CL2015000696A1 (es) 2012-09-20 2015-03-19 Tratamiento para artritis reumatoide
CL2018000933A CL2018000933A1 (es) 2012-09-20 2018-04-12 Una composición farmacéutica que comprende un anticuerpo anti-factor estimulante de colonias de granulocitos-macrógagos (anti-gm-csf) y vehículos, excipientes o estabilizadores farmacéuticamente aceptables, útil para tratar artritis reumatoide (divisional de la solicitud 696-2015).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2015000696A CL2015000696A1 (es) 2012-09-20 2015-03-19 Tratamiento para artritis reumatoide

Country Status (22)

Country Link
US (4) US20150246969A1 (es)
EP (3) EP3916013A1 (es)
JP (4) JP2015533806A (es)
KR (4) KR20230041086A (es)
CN (2) CN104995210A (es)
AU (2) AU2013320261A1 (es)
BR (1) BR112015006189B1 (es)
CL (2) CL2015000696A1 (es)
CR (1) CR20150153A (es)
DO (1) DOP2015000070A (es)
EA (1) EA031489B1 (es)
HK (1) HK1208231A1 (es)
IL (1) IL237554B (es)
IN (1) IN2015KN00657A (es)
MA (1) MA37946B1 (es)
MX (2) MX382937B (es)
MY (1) MY175388A (es)
PE (1) PE20151079A1 (es)
PH (1) PH12015500591A1 (es)
SG (2) SG10201803778PA (es)
UA (1) UA117228C2 (es)
WO (1) WO2014044768A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3916013A1 (en) * 2012-09-20 2021-12-01 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
RU2714919C2 (ru) 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
US11299528B2 (en) * 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
AR100268A1 (es) * 2014-05-07 2016-09-21 Takeda Gmbh Formulación líquida que comprende compuesto neutralizante de gm-csf
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
AU2017248264B2 (en) 2016-04-07 2020-01-30 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
PL3328887T3 (pl) 2016-09-19 2021-12-27 I-Mab Biopharma (Hangzhou) Co., Ltd. Przeciwciała anty-gm-csf i ich zastosowania
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2025218746A1 (en) * 2024-04-17 2025-10-23 Sinomab Bioscience Limited Methods of treating rheumatoid arthritis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP2001501619A (ja) 1996-10-04 2001-02-06 アムジェン インコーポレーテッド ｍｐｌリガンドを含有する医薬組成物
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
NZ564027A (en) 2005-05-18 2011-06-30 Morphosys Ag Anti-GM-CSF antibodies and uses therefor
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
WO2008042261A2 (en) * 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anti-anthrax antibody, formulations thereof, and methods of use
CN101605547A (zh) * 2006-11-21 2009-12-16 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗慢性炎症疾病的方法
US20100209434A1 (en) * 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
AR065910A1 (es) * 2007-04-02 2009-07-08 Genentech Inc Marcadores biologicos pronosticos de la respuesta de la artritis reumatoide a los antagonistas de los linfocitos b
WO2008122415A1 (en) 2007-04-05 2008-10-16 Sandoz Ag Stable aqueous g-csf formulations
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
MX2010005291A (es) 2007-11-13 2010-11-12 Evec Inc Anticuerpos monoclonales que se unen a hgm-csf y composiciones medicas que comprenden los mismos.
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
ES2978209T3 (es) * 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
EP2427495A1 (en) * 2009-05-05 2012-03-14 MorphoSys AG Treatment for multiple sclerosis
RS53010B (sr) 2009-12-31 2014-04-30 Arven Ilac Sanayi Ve Ticaret A.S. Novi postupak za pripremu g-csf (faktora stimulacije kolonije granulocita)
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
CN103827143A (zh) 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
EP3916013A1 (en) * 2012-09-20 2021-12-01 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody

Also Published As

Publication number Publication date
PH12015500591B1 (en) 2015-05-11
MX2015003644A (es) 2015-09-25
UA117228C2 (uk) 2018-07-10
MX382937B (es) 2025-03-13
KR20220028177A (ko) 2022-03-08
AU2016250388B2 (en) 2018-07-19
CL2015000696A1 (es) 2015-10-23
US20210130451A1 (en) 2021-05-06
MA37946A1 (fr) 2018-01-31
US20150246969A1 (en) 2015-09-03
MA37946B1 (fr) 2018-09-28
JP2018138551A (ja) 2018-09-06
EP2897977A1 (en) 2015-07-29
IL237554A0 (en) 2015-04-30
AU2016250388A1 (en) 2016-11-17
US20180230208A1 (en) 2018-08-16
HK1208231A1 (en) 2016-02-26
US10913792B2 (en) 2021-02-09
IN2015KN00657A (es) 2015-07-17
KR20230041086A (ko) 2023-03-23
WO2014044768A1 (en) 2014-03-27
CA2884124A1 (en) 2014-03-27
SG10201803778PA (en) 2018-06-28
CN109999195A (zh) 2019-07-12
KR20240091288A (ko) 2024-06-21
JP2022169709A (ja) 2022-11-09
BR112015006189A2 (pt) 2019-11-26
IL237554B (en) 2019-12-31
KR20150056846A (ko) 2015-05-27
BR112015006189B1 (pt) 2022-04-05
EP3345923A1 (en) 2018-07-11
CN104995210A (zh) 2015-10-21
EA201590359A1 (ru) 2015-08-31
DOP2015000070A (es) 2015-08-16
PH12015500591A1 (en) 2015-05-11
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
JP2024156992A (ja) 2024-11-06
MX2021006111A (es) 2021-07-07
EA031489B1 (ru) 2019-01-31
US20240417455A1 (en) 2024-12-19
EP3916013A1 (en) 2021-12-01
CR20150153A (es) 2015-09-14
JP2015533806A (ja) 2015-11-26
PE20151079A1 (es) 2015-08-07
AU2013320261A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
AR132864A2 (es) UN ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A a-SINUCLEÍNA HUMANA, UN ANTICUERPO HUMANIZADO, UNA FORMULACIÓN FARMACÉUTICA QUE COMPRENDE EL ANTICUERPO, Y LA UTILIZACIÓN DEL ANTICUERPO
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
ECSP22034515A (es) FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7
CL2020001579A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. (divisional solicitud 201303145)
CL2016000324A1 (es) Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1.
PE20141568A1 (es) Anticuerpos humanizados que reconocen la alfa-sinucleina
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20142407A1 (es) Formulacion de anticuerpos
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
PE20141537A1 (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos
PE20161390A1 (es) Anticuerpos multiespecificos
PE20150002A1 (es) Anticuerpos anti-fcrn
ES2620264T3 (es) Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
UA113728C2 (xx) Фармацевтична композиція, яка містить антитіло до pcsk9 людини
AR084315A1 (es) Anticuerpos anti-notch1
PE20170900A1 (es) Metodos y formulaciones para tratar enfermedades vasculares de los ojos
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
MX349198B (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
PE20150159A1 (es) Composiciones y metodos para anticuerpos que actuan sobre el factor p
PE20141028A1 (es) Nuevos moduladores y metodos para su uso
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
PE20142046A1 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AR096687A1 (es) Anticuerpos anti-fcrh5